Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report

Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report

Germ cell tumors (GCTs) represent about 5% of urological cancers affecting mostly younger males with increasing incidence in the last decades. GCTs are very sensitive to cisplatin-based therapy and are highly curable regardless of metastatic stage, likely based on having inherited unique mechanisms...

Full description

Saved in:
Bibliographic Details
Main Authors: Nils C. H. van Creij, Gerald Klinglmair, Leonhard Gruber, Antonia Partl, Alain G. Zeimet, Frédéric R. Santer, Simon Schnaiter, Roman Mayr, Felizian Lackner, Zoran Culig, Andreas Seeber, Renate Pichler
Format: Article
Language:English
Published: SAGE Publishing 2025-03-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/17562872251322648
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17562872251322648

Similar Items